# FDA Inspection 1201815 - GlaxoSmithKline Biologicals Kft. - February 13, 2023

Source: https://www.keypedia.com/records/fda_inspections/glaxosmithkline-biologicals-kft/c5748a37-e9f3-4d62-bbd5-85a709d0645d
Source feed: FDA_Inspections

> FDA Inspection 1201815 for GlaxoSmithKline Biologicals Kft. on February 13, 2023. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1201815
- Company Name: GlaxoSmithKline Biologicals Kft.
- Inspection Date: 2023-02-13
- Classification: No Action Indicated (NAI)
- Project Area: Vaccines and Allergenic Products
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1259740 - 2025-01-31](https://www.keypedia.com/records/fda_inspections/glaxosmithkline-biologicals-kft/9527ac70-cd7e-4bbd-94d5-761289fdbaa8)
- [FDA Inspection 1259740 - 2025-01-31](https://www.keypedia.com/records/fda_inspections/glaxosmithkline-biologicals-kft/d178014b-53d9-44ab-8963-e083051696bc)
- [FDA Inspection 947992 - 2015-10-06](https://www.keypedia.com/records/fda_inspections/glaxosmithkline-biologicals-kft/1d6377f7-17c6-499c-918e-72e70e250131)

Company: https://www.keypedia.com/companies/glaxosmithkline-biologicals-kft/3426122d-c02e-49e7-860c-6ff5237018d3

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d